
Feature|Articles|October 10, 2025
5 Key Takeaways on Most Favored Nations Pricing From MJH Life Sciences Webinar
Author(s)Briana Contreras
Experts discuss the implications of Most Favored Nation pricing on U.S. drug costs, innovation and patient access in the latest MJH Life Sciences webinar.
Advertisement
Advertisement
Most Favored Nation (MFN) pricing represents a major shift in U.S. drug policy. While intended to make medications more affordable, experts during an MFN 2025 webinar warned it could slow innovation, especially in oncology, and disrupt the balance of the healthcare system. Legal challenges, interactions with the IRA and 340B programs and how insurance covers medications will shape its impact on patients, payers and drug companies.
Related to this article

Blood RNA risk score from 31 small RNAs flags Lung Cancer in smokers up to 10 years early, potentially guiding earlier LDCT screening.

The CEO and founder of a digital behavior company has advice for health plans considering asynchronous behavioral health services like those that his company provides.

In this interview, Melody Chang, RPh, BCOP, MBA, vice president of pharmacy operation at the American Oncology Network, discusses the network's pharmacy strategy and priorities.

The purchase comes as the "big 3" drug wholesalers are coming under scrutiny for their market dominance and the possible perils of vertical integration.

In this discussion, Heather Burrell-Ward, M.D., provides an overview of her recent study that found TMS aimed at the default mode network improved processing speed in schizophrenia.

Rand researchers identify standardizing supplemental benefits, limiting the number of plans an insurer can market and reforming broker commissions as policy proposals that would benefit beneficiaries while not harming the government or the plans.
Advertisement
Advertisement


